MCID: CHL028
MIFTS: 60

Childhood Type Dermatomyositis

Categories: Blood diseases, Bone diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Childhood Type Dermatomyositis

MalaCards integrated aliases for Childhood Type Dermatomyositis:

Name: Childhood Type Dermatomyositis 12 15
Juvenile Dermatomyositis 12 74 52 58 17 71 32
Juvenile Dm 52 58
Dermatomyositis, Childhood Type 71
Childhood Dermatomyositis 12

Characteristics:

Orphanet epidemiological data:

58
juvenile dermatomyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Worldwide); Age of onset: Adolescent,Childhood,Infancy; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases
Rare skin diseases


Summaries for Childhood Type Dermatomyositis

NIH Rare Diseases : 52 Juvenile dermatomyositis has some similarities to adult dermatomyositis and polymyositis . It typically affects children ages 2 to 15 years, with symptoms that include weakness of the muscles close to the trunk of the body, inflammation, edema , muscle pain, fatigue, skin rashes, abdominal pain, fever, and contractures . Children with juvenile dermatomyositis may have difficulty swallowing and breathing, and the heart may also be affected. About 20 to 30 percent of children with juvenile dermatomyositis develop calcium deposits in the soft tissue . Affected children may not show higher than normal levels of the muscle enzyme creatine kinase in their blood but have higher than normal levels of other muscle enzymes. Treatment is aimed at addressing the individual symptoms of each patient. This may involve a combination of medications, physical therapy and supplements.

MalaCards based summary : Childhood Type Dermatomyositis, also known as juvenile dermatomyositis, is related to interstitial lung disease and enthesopathy. An important gene associated with Childhood Type Dermatomyositis is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Akt Signaling and PAK Pathway. The drugs Abatacept and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, skin and bone, and related phenotypes are muscle weakness and fatigue

Wikipedia : 74 Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy (IMM) of presumed autoimmune... more...

Related Diseases for Childhood Type Dermatomyositis

Diseases related to Childhood Type Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 420)
# Related Disease Score Top Affiliating Genes
1 interstitial lung disease 31.1 TRIM21 TNF MORC3 IFIH1
2 enthesopathy 30.8 TNFRSF1B TNF CCR6
3 pustulosis of palm and sole 30.7 TNFRSF1B TNF CCR6
4 rheumatic disease 30.5 TRIM21 TNFRSF1B TNF ICOSLG CCR6
5 macrophage activation syndrome 30.5 TNFRSF1B TNF
6 autoimmune vasculitis 30.5 TNF CD4 CCR6
7 calcinosis 30.3 TNF PIK3C2A HLA-DQA1
8 autoimmune gastritis 30.2 TNF CD4 CCR6
9 mixed connective tissue disease 30.1 TNF SNRNP70 HLA-DQA1
10 cellulitis 30.1 TNF ICOSLG CD4 CCR6
11 skin disease 30.1 TNFRSF1B TNF MX1 ICOSLG CXCR3 CD4
12 herpes zoster 29.9 TNFRSF1B TNF ICOSLG CD4
13 mumps 29.9 TNFRSF1B TNF MX1
14 celiac disease 1 29.8 TNF ICOSLG HLA-DQA1 CD4 CCR6
15 bacterial infectious disease 29.8 TNF MX1 ICOSLG CD4 CCR6
16 uveitis 29.8 TNFRSF1B TNF CXCR5 CXCR3
17 chickenpox 29.8 TNFRSF1B TNF ICOSLG CD4 CCR6
18 lupus erythematosus 29.8 TRIM21 TNFRSF1B TNF SNRNP70 MX1 HLA-DQA1
19 adult dermatomyositis 29.6 TRIM33 TRIM24 TNF MORC3 IFIH1 DMBX1
20 psoriasis 29.6 TNFRSF1B TNF MIR10A IFIH1 CXCR3 CD4
21 dermatitis, atopic 29.6 TNF ICOSLG CXCR3 CD4 CCR6
22 central nervous system disease 29.5 TNF MIR10A ICOSLG CXCR3 CD4 CCR6
23 nervous system disease 29.5 TNF MIR10A ICOSLG CXCR3 CD4 CCR6
24 juvenile rheumatoid arthritis 29.5 TNFRSF1B TNF HLA-DQA1
25 systemic scleroderma 29.3 TRIM21 TNF SNRNP70 ICOSLG EXOSC10 CD4
26 primary biliary cirrhosis 29.3 TNF HLA-DQA1 CXCR5 CXCR3 CD4
27 myositis 29.0 TRIM33 TRIM21 TNF PIK3C2A IFIH1 ICOSLG
28 connective tissue disease 29.0 TNFRSF1B TNF SNRNP70 ICOSLG HLA-DQA1 CD4
29 exanthem 28.8 TRIM21 TNFRSF1B TNF PIK3C2A IFIH1 ICOSLG
30 autoimmune disease 28.6 TRIM21 TNFRSF1B TNF IFIH1 ICOSLG HLA-DQA1
31 rheumatoid arthritis 28.4 TNFRSF1B TNF HLA-DQA1 CXCR5 CXCR3 CD4
32 systemic lupus erythematosus 28.4 TRIM21 TNFRSF1B TNF SNRNP70 MX1 IFIH1
33 muscular disease 28.2 TRIM33 TRIM21 TNFRSF1B TNF SNRNP70 PIK3C2A
34 dermatomyositis 10.6
35 juvenile overlap myositis 10.5
36 lung disease 10.5
37 mikulicz disease 10.5 ICOSLG CD4 CCR6
38 subacute cutaneous lupus erythematosus 10.5 TRIM21 TNF
39 dacryoadenitis 10.4 ICOSLG CD4 CCR6
40 autoimmune glomerulonephritis 10.4 ICOSLG CD4 CCR6
41 facial hemiatrophy 10.4 SNRNP70 EXOSC10
42 myelitis 10.4 TNF ICOSLG CCR6
43 nut allergy 10.4 ICOSLG CD4 CCR6
44 monoclonal gammopathy of uncertain significance 10.4 TNF ICOSLG CCR6
45 thrombocytopenia due to platelet alloimmunization 10.4 ICOSLG CD4 CCR6
46 igg4-related disease 10.4 ICOSLG CD4 CCR6
47 autoimmune disease of skin and connective tissue 10.4 ICOSLG CD4 CCR6
48 primary thrombocytopenia 10.4 ICOSLG CD4 CCR6
49 autoimmune disease of blood 10.4 ICOSLG CD4 CCR6
50 immunoglobulin alpha deficiency 10.4 ICOSLG CD4 CCR6

Graphical network of the top 20 diseases related to Childhood Type Dermatomyositis:



Diseases related to Childhood Type Dermatomyositis

Symptoms & Phenotypes for Childhood Type Dermatomyositis

Human phenotypes related to Childhood Type Dermatomyositis:

58 31 (show all 47)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 muscle weakness 58 31 hallmark (90%) Very frequent (99-80%) HP:0001324
2 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
3 dry skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0000958
4 skin rash 58 31 hallmark (90%) Very frequent (99-80%) HP:0000988
5 erythema 58 31 hallmark (90%) Very frequent (99-80%) HP:0010783
6 telangiectasia of the skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0100585
7 autoimmunity 58 31 hallmark (90%) Very frequent (99-80%) HP:0002960
8 myalgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003326
9 mucosal telangiectasiae 58 31 hallmark (90%) Very frequent (99-80%) HP:0100579
10 myositis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100614
11 palpebral edema 58 31 hallmark (90%) Very frequent (99-80%) HP:0100540
12 elevated c-reactive protein level 58 31 hallmark (90%) Very frequent (99-80%) HP:0011227
13 elevated erythrocyte sedimentation rate 58 31 hallmark (90%) Very frequent (99-80%) HP:0003565
14 calcinosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0003761
15 elevated serum creatine kinase 31 hallmark (90%) HP:0003236
16 constipation 58 31 frequent (33%) Frequent (79-30%) HP:0002019
17 muscular hypotonia 58 31 frequent (33%) Frequent (79-30%) HP:0001252
18 arthritis 58 31 frequent (33%) Frequent (79-30%) HP:0001369
19 alopecia 58 31 frequent (33%) Frequent (79-30%) HP:0001596
20 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
21 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
22 pruritus 58 31 frequent (33%) Frequent (79-30%) HP:0000989
23 cutaneous photosensitivity 58 31 frequent (33%) Frequent (79-30%) HP:0000992
24 skin ulcer 58 31 frequent (33%) Frequent (79-30%) HP:0200042
25 restrictive ventilatory defect 58 31 frequent (33%) Frequent (79-30%) HP:0002091
26 vasculitis 58 31 frequent (33%) Frequent (79-30%) HP:0002633
27 poikiloderma 58 31 frequent (33%) Frequent (79-30%) HP:0001029
28 muscle spasm 31 frequent (33%) HP:0003394
29 dysarthria 58 31 occasional (7.5%) Occasional (29-5%) HP:0001260
30 dysphonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001618
31 dysphagia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002015
32 pulmonary fibrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002206
33 dyspnea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002094
34 emg abnormality 58 31 occasional (7.5%) Occasional (29-5%) HP:0003457
35 arrhythmia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011675
36 angina pectoris 58 31 occasional (7.5%) Occasional (29-5%) HP:0001681
37 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
38 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
39 limitation of joint mobility 58 31 occasional (7.5%) Occasional (29-5%) HP:0001376
40 pericarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001701
41 gastrointestinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002239
42 cough 58 31 occasional (7.5%) Occasional (29-5%) HP:0012735
43 cardiomyopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001638
44 bundle branch block 58 31 occasional (7.5%) Occasional (29-5%) HP:0011710
45 hoarse voice 58 31 occasional (7.5%) Occasional (29-5%) HP:0001609
46 elevated serum creatine phosphokinase 58 Very frequent (99-80%)
47 muscle cramps 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Childhood Type Dermatomyositis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 CCR6 CCRL2 CD4 CXCR3 CXCR5 HLA-DQA1
2 immune system MP:0005387 9.4 CCR6 CCRL2 CD4 CXCR3 CXCR5 HLA-DQA1

Drugs & Therapeutics for Childhood Type Dermatomyositis

Drugs for Childhood Type Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4 332348-12-6 10237
2 Vaccines Phase 4
3 Immunologic Factors Phase 4
4 Antirheumatic Agents Phase 4
5 Immunosuppressive Agents Phase 4
6 Melanocyte-Stimulating Hormones Phase 4
7 Adrenocorticotropic Hormone Phase 4
8 beta-endorphin Phase 4
9
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
10
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
11
Alendronate Approved Phase 2, Phase 3 121268-17-5, 66376-36-1 2088
12
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
13
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
14
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
15 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
16
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
17
Methotrexate Approved Phase 2, Phase 3 1959-05-2, 59-05-2 126941
18
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
19
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
20
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
22
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
23 Cyclosporins Phase 3
24 Antifungal Agents Phase 3
25 Calcineurin Inhibitors Phase 3
26 Methylprednisolone Acetate Phase 3
27 glucocorticoids Phase 2, Phase 3
28 Folic Acid Antagonists Phase 2, Phase 3
29 Vitamin B9 Phase 2, Phase 3
30 Vitamin B Complex Phase 2, Phase 3
31 Dermatologic Agents Phase 2, Phase 3
32 Folate Phase 2, Phase 3
33 Hormone Antagonists Phase 2, Phase 3
34 Gastrointestinal Agents Phase 2, Phase 3
35 Antineoplastic Agents, Hormonal Phase 2, Phase 3
36 Antimetabolites Phase 2, Phase 3
37 Anti-Inflammatory Agents Phase 2, Phase 3
38 Hormones Phase 2, Phase 3
39 Analgesics Phase 2, Phase 3
40 Analgesics, Non-Narcotic Phase 2, Phase 3
41 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
42
rituximab Approved Phase 2 174722-31-7 10201696
43
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
44 Antiemetics Phase 2
45 Neuroprotective Agents Phase 2
46 Autonomic Agents Phase 2
47 Pharmaceutical Solutions Phase 2
48 Antineoplastic Agents, Immunological Phase 2
49 Anti-Infective Agents Phase 2
50 Protective Agents Phase 2

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
3 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
4 Abatacept for the Treatment of Refractory Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
5 Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
6 Double Blind Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid-Associated Osteopenia and Osteoporosis Unknown status NCT00209469 Phase 2, Phase 3 alendronate sodium
7 Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis Completed NCT00277251 Phase 2, Phase 3 Alendronate
8 A Prospective, Randomised, Assessor-blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis. Completed NCT00651040 Phase 3 Prednisone;Methotrexate
9 Toward Improved Understanding of Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
10 Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
11 Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis Completed NCT01572844 Phase 2 Sodium thiosulfate
12 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Completed NCT02043548 Phase 2 tocilizumab;placebo
13 Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM) Completed NCT00106184 Phase 2 Rituximab;Placebo
14 An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
15 Efficacy and Safety of Creatine Supplementation in Patients With Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis Unknown status NCT01217320
16 Studies on Tissues From Patients With Fibrous Dysplasia of Bone/McCune-Albright Syndrome and Other Disorders of Calcified Tissues Completed NCT00001973
17 Fatigue and Sleep in Children and Adolescents With Juvenile Idiopathic Arthritis: A Cross-Sectional Study Completed NCT03618680
18 The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis Completed NCT02267005
19 Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area Completed NCT03430388
20 The CARRA Registry Completed NCT01697254
21 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study (STOPP-CIS) Completed NCT01663129
22 Incidence and Prevalence of Juvenile Dermatomyositis in Alsace Between 2000 to 2015 Recruiting NCT03432455
23 Retrospective Descriptive Study of Juvenile Dermatomyositis in Alsace Recruiting NCT03433638
24 Studies of Natural History, Pathogenesis, and Outcomes in Autoimmune and Inflammatory Diseases Including Juvenile Dermatomyositis Recruiting NCT00059748
25 Pathogenic Studies In Families With Twins Or Siblings Discordant For Systemic Rheumatic Disorders Recruiting NCT00055055
26 MYOPROSP: A Prospective Cohort Study to Identify a Stratified Approach in the Diagnosis, Treatment and Delivery of Care in Adult Idiopathic Inflammatory Myopathy Recruiting NCT02468895
27 Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis No longer available NCT01724580 Baricitinib

Search NIH Clinical Center for Childhood Type Dermatomyositis

Genetic Tests for Childhood Type Dermatomyositis

Anatomical Context for Childhood Type Dermatomyositis

MalaCards organs/tissues related to Childhood Type Dermatomyositis:

40
Skeletal Muscle, Skin, Bone, Heart, Lung, T Cells, B Cells

Publications for Childhood Type Dermatomyositis

Articles related to Childhood Type Dermatomyositis:

(show top 50) (show all 1086)
# Title Authors PMID Year
1
Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. 61
31302187 2020
2
Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. 61
31707357 2020
3
Severe Abdominal Manifestations in Juvenile Dermatomyositis. 61
31978027 2020
4
Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study. 61
31507092 2020
5
Neutrophil Extracellular Traps in Tissue and Periphery in Juvenile Dermatomyositis. 61
31403247 2020
6
Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update. 61
31955618 2020
7
Visual Dermatology: Gottron Papules in a Child: Juvenile Dermatomyositis. 61
31994926 2020
8
Juvenile Dermatomyositis and Development of Malignancy: 2 Case Reports and a Literature Review. 61
31941800 2020
9
Hypopigmentation in the Medial Angle of Eyes in a Young Boy With Juvenile Dermatomyositis. 61
31977652 2020
10
Case Report of a Rare Case of Juvenile Dermatomyositis Sine Dermatitis. 61
31979712 2020
11
Inhibition of IFNα secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technology. 61
31971592 2020
12
Scrotal and Penile Ulcer in Juvenile Dermatomyositis: An Unusual Occurrence. 61
29561468 2020
13
Patient and physician discordance of global disease assessment in juvenile dermatomyositis: findings from the Childhood Arthritis & Rheumatology Research Alliance Legacy Registry. 61
31941511 2020
14
Juvenile dermatomyositis resembling late-stage Degos disease with gastrointestinal perforations successfully treated with combination of cyclophosphamide and rituximab: case-based review. 61
31900501 2020
15
Pamidronate in Treatment of Calcinosis in Juvenile Dermatomyositis. 61
31937708 2020
16
Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies. 61
31292651 2020
17
Juvenile Dermatomyositis-Clinical Phenotypes. 61
31828535 2019
18
Strength training and aerobic exercise training for muscle disease. 61
31808555 2019
19
Long-term outcome in children with juvenile dermatomyositis: A single-center study from north India. 61
31793219 2019
20
Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. 61
31874111 2019
21
Epidemiology of juvenile dermatomyositis in Alsace. 61
31823358 2019
22
Advances Toward Precision Medicine in Juvenile Dermatomyositis. 61
31813083 2019
23
[Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review]. 61
31795559 2019
24
Association of Short-Term Ultraviolet Radiation Exposure and Disease Severity in Juvenile Dermatomyositis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. 61
30714338 2019
25
Juvenile dermatomyositis and pneumomediastinum: a case of a very rare complication. 61
31883798 2019
26
Pain, functional disability, and their Association in Juvenile Fibromyalgia Compared to other pediatric rheumatic diseases. 61
31694655 2019
27
Reply: Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. 61
31603183 2019
28
An international survey of developing classification criteria for juvenile dermatomyositis-scleroderma overlap. 61
31199482 2019
29
Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. 61
31603187 2019
30
Polymyxin-B Hemoperfusion as a Novel Treatment for Rapidly Progressive Interstitial Lung Disease in a Pediatric Patient Diagnosed With Anti-MDA5 Juvenile Dermatomyositis. 61
31743264 2019
31
Using the tools of proteomics to understand the pathogenesis of idiopathic inflammatory myopathies. 61
31385878 2019
32
Functional and Structural Adaptations of Skeletal Muscle in Long-Term Juvenile Dermatomyositis; a Controlled Cross-Sectional Study. 61
31746550 2019
33
Treatment of calcinosis associated with adult and juvenile dermatomyositis using topical sodium thiosulfate via fractionated CO2 laser treatment. 61
31796160 2019
34
Severe Abdominal Manifestations in Juvenile Dermatomyositis. 61
31789774 2019
35
Serum KL-6 level as a biomarker of interstitial lung disease in childhood connective tissue diseases: a pilot study. 61
31784789 2019
36
Novel associations between cytokines and pulmonary involvement in juvenile dermatomyositis - a cross-sectional study of long-term disease. 61
31740970 2019
37
Calcinosis in Juvenile Dermatomyositis. 61
31618543 2019
38
Vaccination coverage in children with rheumatic diseases. 61
31577215 2019
39
Image Gallery: Antihelix red-violaceous macules in juvenile dermatomyositis associated with antimelanoma differentiation-associated protein 5 antibody. 61
31598963 2019
40
Inhibition of IFNα secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technology. 61
31665500 2019
41
Tertiary lymphoid organs in the inflammatory myopathy associated with PD-1 inhibitors. 61
31533865 2019
42
Juvenile dermatomyositis associated with anti-melanoma differentiation-associated gene 5 antibody positivity without complications of interstitial lung disease during the clinical course: A case report. 61
30869164 2019
43
[Pediatric and adolescent rheumatology-A rapidly developing field in pediatrics : Current status of juvenile idiopathic arthritis and juvenile dermatomyositis]. 61
31482211 2019
44
Macrophage activation syndrome in juvenile dermatomyositis: a systematic review. 61
31529231 2019
45
Clinical significance of subcutaneous fat and fascial involvement in juvenile dermatomyositis. 61
30092673 2019
46
Prevalence of Epstein-Barr virus infection and characteristics of lymphocyte subsets in newly onset juvenile dermatomyositis. 61
31549298 2019
47
Subcutaneous edema in juvenile dermatomyositis. 61
28709855 2019
48
Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. 61
31556011 2019
49
[Juvenile dermatomyositis-what's new?] 61
31087132 2019
50
Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan. 61
30092736 2019

Variations for Childhood Type Dermatomyositis

Expression for Childhood Type Dermatomyositis

LifeMap Discovery
Genes differentially expressed in tissues of Childhood Type Dermatomyositis patients vs. healthy controls: 35 (show all 35)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 Skeletal Muscle + 5.58 0.000
2 ISG15 ISG15 ubiquitin-like modifier Skeletal Muscle + 5.25 0.000
3 XIST X inactive specific transcript (non-protein coding) Skeletal Muscle + 5.14 0.000
4 RSAD2 radical S-adenosyl methionine domain containing 2 Skeletal Muscle + 4.94 0.000
5 GBP1 guanylate binding protein 1, interferon-inducible Skeletal Muscle + 4.88 0.000
6 CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial Skeletal Muscle + 4.61 0.000
7 IFI44L interferon-induced protein 44-like Skeletal Muscle + 4.42 0.000
8 MX1 MX dynamin-like GTPase 1 Skeletal Muscle + 4.40 0.000
9 IFI44 interferon-induced protein 44 Skeletal Muscle + 4.34 0.000
10 IFIT2 interferon-induced protein with tetratricopeptide repeats 2 Skeletal Muscle + 3.96 0.000
11 IFI27 interferon, alpha-inducible protein 27 Skeletal Muscle + 3.86 0.000
12 CXCL11 chemokine (C-X-C motif) ligand 11 Skeletal Muscle + 3.67 0.000
13 RPS4Y1 ribosomal protein S4, Y-linked 1 Skeletal Muscle - 3.57 0.000
14 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 Skeletal Muscle + 3.57 0.000
15 MYH3 myosin, heavy chain 3, skeletal muscle, embryonic Skeletal Muscle + 3.54 0.000
16 SAMHD1 SAM domain and HD domain 1 Skeletal Muscle + 3.52 0.000
17 XAF1 XIAP associated factor 1 Skeletal Muscle + 3.44 0.000
18 KLHDC7B kelch domain containing 7B Skeletal Muscle + 3.44 0.000
19 IFI6 interferon, alpha-inducible protein 6 Skeletal Muscle + 3.43 0.000
20 IFIH1 interferon induced with helicase C domain 1 Skeletal Muscle + 3.43 0.000
21 PARP12 poly (ADP-ribose) polymerase family, member 12 Skeletal Muscle + 3.41 0.000
22 IFI16 interferon, gamma-inducible protein 16 Skeletal Muscle + 3.40 0.000
23 PLSCR1 phospholipid scramblase 1 Skeletal Muscle + 3.37 0.000
24 STAT1 signal transducer and activator of transcription 1, 91kDa Skeletal Muscle + 3.37 0.000
25 PSMB8 proteasome subunit beta 8 Skeletal Muscle + 3.35 0.000
26 NNMT nicotinamide N-methyltransferase Skeletal Muscle + 3.31 0.000
27 TRIM22 tripartite motif containing 22 Skeletal Muscle + 3.27 0.000
28 DTX3L deltex 3 like, E3 ubiquitin ligase Skeletal Muscle + 3.23 0.000
29 EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 Skeletal Muscle + 3.14 0.000
30 IRF7 interferon regulatory factor 7 Skeletal Muscle + 3.13 0.000
31 OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa Skeletal Muscle + 3.09 0.000
32 IFITM1 interferon induced transmembrane protein 1 Skeletal Muscle + 3.06 0.000
33 TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 Skeletal Muscle + 3.05 0.000
34 PARP9 poly (ADP-ribose) polymerase family, member 9 Skeletal Muscle + 3.05 0.000
35 POSTN periostin, osteoblast specific factor Skeletal Muscle + 3.03 0.000
Search GEO for disease gene expression data for Childhood Type Dermatomyositis.

Pathways for Childhood Type Dermatomyositis

Pathways related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.1 TNFRSF1B TNF CXCR5 CXCR3 CD4 CCRL2
2
Show member pathways
12.87 TNFRSF1B TNF CXCR5 CXCR3 CD4 CCRL2
3
Show member pathways
12.51 TNF ICOSLG HLA-DQA1 CXCR5 CD4
4
Show member pathways
12.11 TNFRSF1B TNF ICOSLG HLA-DQA1 CD4
5
Show member pathways
12 PIK3C2A ICOSLG HLA-DQA1 CD4
6
Show member pathways
11.77 TNFRSF1B TNF CXCR5 CXCR3 CCRL2 CCR6
7 10.92 TNF CXCR5 CXCR3 CD4 CCR6

GO Terms for Childhood Type Dermatomyositis

Cellular components related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.17 TNF ICOSLG CXCR5 CXCR3 CD4 CCRL2

Biological processes related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemotaxis GO:0006935 9.67 CXCR5 CXCR3 CCRL2 CCR6
2 positive regulation of cytosolic calcium ion concentration GO:0007204 9.62 CXCR5 CXCR3 CCRL2 CCR6
3 cell chemotaxis GO:0060326 9.56 CXCR5 CXCR3 CCRL2 CCR6
4 calcium-mediated signaling GO:0019722 9.46 CXCR5 CXCR3 CCRL2 CCR6
5 positive regulation of viral entry into host cell GO:0046598 9.4 TRIM21 CD4
6 chemokine-mediated signaling pathway GO:0070098 9.26 CXCR5 CXCR3 CCRL2 CCR6
7 immune response GO:0006955 9.23 TNFRSF1B TNF HLA-DQA1 CXCR5 CXCR3 CD4

Molecular functions related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.88 TRIM33 TRIM24 TRIM21 MORC3 IFIH1 CD4
2 identical protein binding GO:0042802 9.87 TRIM21 TNF MX1 IFIH1 ICOSLG CXCR3
3 chemokine binding GO:0019956 9.46 CXCR5 CXCR3 CCRL2 CCR6
4 chemokine receptor activity GO:0004950 9.43 CXCR3 CCRL2 CCR6
5 C-X-C chemokine receptor activity GO:0016494 9.37 CXCR5 CXCR3
6 C-C chemokine binding GO:0019957 9.26 CXCR5 CXCR3 CCRL2 CCR6
7 C-C chemokine receptor activity GO:0016493 8.92 CXCR5 CXCR3 CCRL2 CCR6

Sources for Childhood Type Dermatomyositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....